NTRA

ACCE-researched
Natera Inc. Common Stock
Healthcare · Diagnostics & Research · NASDAQ · United States
$369.39+0.84%
Market cap $53.2BNext earnings 2026-11-05Updated Sep 18, 2026
Not enough applicable valuation models for a consensus. The per-model detail is in the Valuation tab.
ACCE score
55
out of 100
Analysts
95% buy
21 covering
P/E
0.0x
forward -3589.4x
1-year return
+105.4%
Dividend yield
0.00%
Unlock the ACCE read
INVESTOR

Overview

⚠ Investor warnings · 4 flags
  • high
    Extreme valuation, no earnings
    P/S of 15.6x with negative P/E and EV/EBITDA of -26.8x; company still loss-making at -9% net margin.
  • high
    Score spike suspiciously sharp
    ACCE score jumped +48 points in 90 days (5→53); rapid re-ratings can precede volatility or reflect momentum crowding.
  • moderate
    Insider selling, no buying
    Last 10 disclosed transactions show $4.32M in sales and $0 in buys, signalling insiders are reducing exposure.
  • moderate
    Negative operating margin
    Operating margin is -12.4% despite 65.1% gross margin, indicating heavy opex burn relative to revenue scale.
Reports in 45 days, last quarter beat by 0.0%.

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Price

+106.1% · 1Y

Valuation

INVESTOR
Full valuation engine INVESTOR FEATURE

Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.

  • +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
  • +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
  • +Editable DCF workbench with saved scenarios

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.

  • +Conviction score breakdown and earnings-quality grade
  • +Growth / value / quality / momentum component scores
  • +90-day score history and score-threshold backtests

Analysts

Wall Street consensus

Bullish95% buy · 21 covering analysts
● Strong buy 12● Buy 8● Hold 0● Sell 1● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO
Smart money tracking PRO FEATURE

Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Recent open-market insider transactions
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

This stock Peer Peer median weaker → stronger
P/Ebetter than 100% of peers
low 0.0x0.0xhigh 106.5x
ROEbetter than 0% of peers
low -13%-13%high 74%
Div yieldbetter than 67% of peers
low 0.0%0.0%high 0.9%

Algorithmic peers (6)

TickerCompanyMcapP/EROED/EYieldQuality
LONN.SWLonza Group$46.2B35.212.9%0.460.9%-Compare
AAgilent Technologies Inc. Common Stock$44.1B30.921.0%0.500.7%-Compare
IQVIQVIA Holdings Inc. Common Stock$43.9B33.122.8%2.420.0%-Compare
WATWaters Corporation Common Stock$41.4B106.51.9%0.730.0%-Compare
IDXXIDEXX Laboratories Inc. Common Stock$40.3B36.074.2%0.530.0%-Compare
ILMNIllumina Inc. Common Stock$36.2B44.632.3%0.730.0%-Compare

Sector report card

Where NTRA ranks against its sector peers on each metric.

Computing percentiles…

News and Record

Reports in 45 days, last quarter beat by 0.0%.

Press releases mentioning this company

Ask anything, Pro feature

Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.

PRO

Recent performance

1 week
+12.3%
1 month
+13.6%
3 months
+59.6%
6 months
+89.2%
YTD
+61.2%
1 year
+105.4%

SEC filings

40 filings
September 2026
Sep 18
Form 4Insider transactionPeriod 2026-09-16
Sep 17
Form 4Insider transactionPeriod 2026-09-15
Sep 16
Form 4Insider transactionPeriod 2026-09-14
37 more filings + AI summaries on Investor+.INVESTOR